474020-88-7

Basic information

• Product Name: Carbamic acid, methyl(4-nitrophenyl)-, 1,1-dimethylethyl ester
• CAS NO: 474020-88-7
• Molecular Formula: C12H16N2O4
• Molecular Weight: 252.27
• Mol File: 474020-88-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Carbamic acid, methyl(4-nitrophenyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, methyl(4-nitrophenyl)-, 1,1-dimethylethyl ester(474020-88-7)
• EPA Substance Registry System: Carbamic acid, methyl(4-nitrophenyl)-, 1,1-dimethylethyl ester(474020-88-7)

Safety Data

• Hazardous Substances Data: 474020-88-7(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-15-2 N-methyl(p-nitroaniline) 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 1092522-02-5 tert-butyl N-methyl-N-(4-aminophenyl)carbamoate 
• 1448444-80-1 tert-butyl 4-(5-amino-6-(dibenzylamino)pyrimidin-4-ylamino)phenyl(methyl)carbamate 
• 1448444-81-2 tert-butyl 4-(6-(dibenzylamino)-8-oxo-7H-purin-9(8H)-yl)phenyl(methyl)carbamate 
• 1448444-82-3 tert-butyl 4-(6-amino-8-oxo-7H-purin-9(8H)-yl)phenyl(methyl)carbamate 
• 1987887-92-2 methyl (Z)-3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate 
• 656247-17-5 nintedanib 
• 1448444-79-8 tert-butyl 4-(6-(dibenzylamino)-5-nitropyrimidin-4-ylamino)phenyl(methyl)carbamate 
• 100-15-2 N-methyl(p-nitroaniline) 

Relevant articles and documents

Deep imaging for visualizing nitric oxide in lipid droplets: discovering the relationship between nitric oxide and resistance to cancer chemotherapy drugs

A near-infrared two-photon fluorescent probe (TAN) was synthesized for selective detection and deep-depth imaging of NO in lipid droplets. All results demonstrated that NO production in lipid droplets is closely correlated with the resistance to anti-tumor drugs, and NO inhibitors can effectively improve the efficacy of chemotherapeutic agents.

nepal reaches Neeb process and intermediates for the synthesis of (by machine translation)

The invention discloses a method for synthesizing nepal reaches Neeb and intermediates thereof, the synthesis method comprises: under acidic conditions, the compound of formula (II) reaction of a compound of the formula (I) compound of formula (III); compound (III) of the detached with acid uncle Ding Zhiji carbonate, adding alkali reaction of the compound of formula (V); the compound of formula (V) reaction with chloroacetic acid derivatives of formula (VI) the activation of the compound, then the reaction-methyl piperazine N, obtain nepal reaches Neeb. The present invention provides a mild reaction conditions of a new method for synthesizing nepal reaches Neeb, the invention also provides synthetic intermediates nepal reaches Neeb. (by machine translation)

Targeting metal-Aβ aggregates with bifunctional radioligand [11C]L2-b and a fluorine-18 analogue [18F]FL2-b

Interest in quantifying metal-Aβ species in vivo led to the synthesis and evaluation of [11C]L2-b and [18F]FL2-b as radiopharmaceuticals for studying the metallobiology of Alzheimer's disease (AD) using positron emission tomography (PET) imaging. [11C]L2-b was synthesized in 3.6% radiochemical yield (nondecay corrected, n = 3), >95% radiochemical purity, from the corresponding desmethyl precursor. [18F]FL2-b was synthesized in 1.0% radiochemical yield (nondecay corrected, n = 3), >99% radiochemical purity, from a 6-chloro pyridine precursor. Autoradiography experiments with AD positive and healthy control brain samples were used to determine the specificity of binding for the radioligands compared to [11C]PiB, a known imaging agent for β-amyloid (Aβ) aggregates. The Kd for [11C]L2-b and [18F]FL2-b were found to be 3.5 and 9.4 nM, respectively, from those tissue studies. Displacement studies of [11C]L2-b and [18F]FL2-b with PiB and AV-45 determined that L2-b binds to Aβ aggregates differently from known radiopharmaceuticals. Finally, brain uptake of [11C]L2-b was examined through microPET imaging in healthy rhesus macaque, which revealed a maximum uptake at 2.5 min (peak SUV = 2.0) followed by rapid egress (n = 2).